secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001326110-25-000084
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio stockholders approve 2025 Equity Incentive Plan, re-elect directors
-------------------------------------------------------------------------------

- 2025 Equity Incentive Plan approved; reserves 46,088,027 new shares plus up to 32,359,674 from expired/forfeited 2015 Plan awards.
- All eight director nominees re-elected at June 18, 2025 annual meeting; 89% of shares represented.
- Deloitte & Touche ratified as independent auditor for fiscal 2025 with 99.5% votes in favor.
- Plan replaces 2015 Plan; no further awards under prior plan, but existing grants continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000084/0001326110-25-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000084/ibrx-20250618.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer